A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received…

Integrating Non-Communicable Disease (NCD) Screening to COVID-19 and Human Immunodeficiency Virus (HIV) care in Johannesburg South Africa (SA): a pilot model for low- and middle-…

A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen…

Lay user evaluation of the Panbio™ HCV Self Test: A prospective, multi-centre observed untrained user study.   Study Summary This is a prospective, multi-centre study…

Lay user evaluation of the Panbio™ HCV Self Test: A prospective, multi-centre usability study to evaluate lay user labelling comprehension and test result interpretation.  …

Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial   Co-National Principal Investigators Dr Simiso Sokhela (MBChB) Director: Clinical Research, Ezintsha, Wits Health Consortium University of the…

A cross-sectional, observational study to characterise Long-COVID in an urban sample of South African adults Background “Long–COVID’’ (also known as post-COVID-19 syndrome, post-acute sequelae of…

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF compared to DTG/TAF/FTC in Participants Infected with HIV-1 Starting First-line Antiretroviral Therapy Study Sites Multiple sites- in…

A STUDY CONDUCTED TO EVALUATE THE PERFORMANCE OF THE SARS- COV-2 & INFLUENZA A/B ANTIGEN TEST Study Type Pivotal Study for potential CE/FDA EUA/WHO filing…

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on…